Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Jul 10, 2026
TickeronGET DAILY SIGNALS
Tema Oncology ETF (CANC) Rallies +13.6% Amid Key Oncology Advances

Tema Oncology ETF (CANC) Rallies +13.6% Amid Key Oncology Advances

Key Takeaways

  • The Tema Oncology ETF surged approximately 13.6% over the past 30 days, driven by a wave of landmark oncology drug approvals and positive clinical data.
  • Over the last quarter, CANC delivered a total return of roughly 12.2%, reflecting sustained momentum across the biotechnology and precision oncology sectors.
  • The fund's largest holding, Revolution Medicines, saw its stock soar after the FDA approved daraxonrasib—the first-ever targeted therapy for pancreatic cancer—on July 8.
  • Broader strength in holdings such as Gilead Sciences, Guardant Health, and Moderna amplified the rally, fueled by regulatory wins and growing investor enthusiasm for next-generation cancer treatments.
  • The actively managed ETF, which concentrates on companies developing cancer therapeutics and diagnostics, benefited from a powerful sector-wide rotation into oncology and precision medicine names.

Tema Oncology ETF (CANC) Overview and Portfolio Exposure

The Tema Oncology ETF (CANC) is an actively managed exchange-traded fund that invests in biotechnology and pharmaceutical companies shaping the future of cancer treatment and care. Launched in August 2023 and managed by Tema ETFs, the fund is overseen by portfolio manager David K. Song, MD, PhD, CFA, a Penn-trained physician with more than two decades of healthcare investing experience. CANC carries a net expense ratio of 0.75% and held approximately $197 million in assets under management (AUM) as of early July 2026.

The portfolio comprises roughly 58 holdings, with approximately 98% allocated to the healthcare sector. Top positions include Revolution Medicines (6.0%), Eli Lilly (5.0%), Cogent Biosciences (5.0%), Novartis (3.9%), Roche Holding (3.8%), Merck (3.4%), Legend Biotech (3.4%), Immunome (3.3%), Johnson & Johnson (3.3%), and Bristol-Myers Squibb (3.2%). Geographically, U.S.-listed companies represent roughly 75% of assets, with Switzerland, the United Kingdom, and other regions accounting for the remainder. This concentrated exposure to high-conviction oncology names makes CANC particularly responsive to clinical trial outcomes, regulatory decisions, and sector-wide sentiment shifts. From what I see, the structure aligns well with investors focused on precision medicine themes.

Tema Oncology ETF (CANC) Price Performance: Last 30 Days vs. Quarter

Over the 30-day period ending July 10, 2026, CANC climbed approximately 13.6%, rising from a closing price of $36.48 on June 10 to an intraday level near $41.46. The advance was not linear; the ETF experienced a pronounced inflection point in late June that accelerated into early July as multiple portfolio holdings delivered transformative news. The rally was characterized by strong upward momentum rather than gradual grinding, with daily trading volumes expanding notably during the final week of the period.

Looking at the broader quarterly picture, CANC posted a total return of approximately 12.2% for the three months ending June 30, 2026, according to fund data. This performance reflects a sustained recovery and expansion from earlier 2026 levels, supported by a favorable macroeconomic backdrop for growth-oriented biotechnology equities and a series of positive clinical and regulatory catalysts across the oncology landscape. I’m watching this closely as a signal of broader sector rotation.

What Drove CANC Price in the Last 30 Days

The primary catalyst behind CANC's sharp 30-day advance was the historic FDA approval of Revolution Medicines' daraxonrasib on July 8, 2026—the first targeted therapy ever approved for pancreatic cancer. The drug demonstrated a doubling of overall survival in second-line metastatic pancreatic ductal adenocarcinoma, with median overall survival reaching 13.2 months versus 6.7 months for chemotherapy. As CANC's largest holding at roughly 6% of net assets, Revolution Medicines experienced a dramatic stock price surge that directly lifted the ETF's net asset value (NAV).

Several other major holdings contributed meaningfully to the rally. Gilead Sciences advanced after securing U.S. and European approvals for Trodelvy in first-line metastatic triple-negative breast cancer in late June, reinforcing its oncology franchise. Guardant Health surged approximately 14% in a single session after the FDA cleared its Guardant360 CDx liquid biopsy test as a companion diagnostic for a new HER2-mutant lung cancer therapy, marking the platform's 27th companion diagnostic indication. Moderna rallied roughly 40% over the month as the company unveiled an in-vivo CAR-T program and outlined an expanded oncology pipeline during its Science Day presentation. Additionally, Novartis received FDA approval for Scemblix as a first-line treatment for chronic myeloid leukemia—the first new frontline mechanism in that disease since 2001.

Collectively, these developments ignited a powerful sector-wide rotation into oncology and precision medicine equities. Investor sentiment was further bolstered by strong fund flows into healthcare ETFs and growing conviction that the oncology innovation cycle is accelerating. The concentrated, actively managed structure of CANC amplified the impact of these stock-specific catalysts relative to broader healthcare benchmarks. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

What Drove CANC Performance Over the Last Quarter

The quarterly performance of approximately 12.2% was underpinned by a broader recovery in biotechnology equities that began in the spring of 2026. After a period of consolidation in April and May, the sector gained traction as clinical data readouts at major medical conferences—including the American Society of Clinical Oncology (ASCO) annual meeting—reinforced the therapeutic and commercial potential of next-generation oncology platforms. Positive Phase 3 results from Revolution Medicines' daraxonrasib, presented at ASCO and published in the New England Journal of Medicine, set the stage for the subsequent approval and rally.

Macroeconomic conditions also provided a supportive backdrop. Stabilizing interest rate expectations and a risk-on environment favored growth-oriented sectors such as biotechnology. Institutional capital flows into actively managed thematic ETFs increased, with CANC's AUM growing substantially over the period. The fund's emphasis on companies targeting RAS-addicted cancers, antibody-drug conjugates, liquid biopsy diagnostics, and immuno-oncology positioned it at the intersection of several of the most dynamic subsectors within healthcare. This thematic alignment, combined with stock-specific execution from major holdings, drove the sustained quarterly advance.

Using Tickeron’s AI Tools for Sector Research

In my view, tools like Tickeron’s AI Screener can be useful when monitoring fast-moving areas such as oncology. The platform allows filtering by technical indicators, fundamentals, volatility, and AI-generated signals, which helps surface relevant names efficiently without replacing core fundamental analysis. I’ve found it helpful for cross-checking how CANC stacks up against peers during periods of sector rotation.

CANC ETF Outlook: What Investors Should Watch Next

Looking ahead, several factors are likely to influence CANC's trajectory. The commercial launch of daraxonrasib by Revolution Medicines will be closely watched, as the company transitions from a clinical-stage biotech to a commercial oncology enterprise. Early prescription data, payer coverage decisions, and revenue ramp metrics will provide critical signals about the drug's market adoption and, by extension, the valuation of CANC's largest holding.

Beyond individual stock catalysts, the broader oncology regulatory calendar remains active. Additional FDA decisions, European Medicines Agency reviews, and clinical data presentations at major medical meetings could sustain or disrupt sector momentum. The ongoing congressional probe into pharmaceutical companies' China-based clinical trial partnerships introduces a layer of geopolitical risk, though deal flow between Western and Chinese biotech firms has continued largely uninterrupted. Macroeconomic variables—particularly interest rate policy and inflation trends—will also influence the risk appetite for growth-oriented biotechnology equities. While the recent rally reflects genuine therapeutic breakthroughs, the concentrated nature of CANC's portfolio means that setbacks affecting any major holding could produce outsized downside moves. Investors should monitor these dynamics while recognizing that the fund's active management provides a degree of adaptability in responding to changing market conditions.

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CANC

Contributor

My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.


CANC's RSI Indicator is remaining in oversold zone for 1 day

It is expected that a price bounce should occur soon.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +6.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where CANC advanced for three days, in 174 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.

CANC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 133 of 155 cases where CANC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 86%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CANC as a result. In 46 of 57 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 81%.

The Moving Average Convergence Divergence Histogram (MACD) for CANC turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 28 similar instances when the indicator turned negative. In 25 of the 28 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.

CANC moved below its 50-day moving average on November 12, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for CANC crossed bearishly below the 50-day moving average on November 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 82%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CANC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Bristol-Myers Squibb Co (NYSE:BMY), Guardant Health (NASDAQ:GH), Exelixis (NASDAQ:EXEL).

Industry description

The investment seeks to provide long-term growth. Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.

Market Cap

The average market capitalization across the Tema Oncology ETF (CANC) ETF is 68.56B. The market cap for tickers in the group ranges from 340.69M to 1.21T. LLY holds the highest valuation in this group at 1.21T. The lowest valued company is AUTL at 340.69M.

High and low price notable news

The average weekly price growth across all stocks in the Tema Oncology ETF (CANC) ETF was -9%. For the same ETF, the average monthly price growth was -10%, and the average quarterly price growth was -2%. CGON experienced the highest price growth at 7%, while SMMT experienced the biggest fall at -30%.

Volume

The average weekly volume growth across all stocks in the Tema Oncology ETF (CANC) ETF was 50%. For the same stocks of the ETF, the average monthly volume growth was 33% and the average quarterly volume growth was -4%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 46
Price Growth Rating: 56
SMR Rating: 80
Profit Risk Rating: 75
Seasonality Score: -2 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Interact to see
Advertisement
SSO is a 2x daily leveraged ETF (exchange-traded fund) that seeks double the daily return of the S&P 500, while XXX is a non-leveraged, passive fund blending roughly 75% S&P 500 exposure with 25% XRP, a major cryptocurrency. Both funds charge comparable fees — about 0.87% for SSO and roughly 0.85% for XXX — but their risk profiles are fundamentally different.
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.